Evidence map›Paper›PMID 27293830›Full record

ArticleJournal of thoracic disease2016

Survival impact of locoregional metachronous malignancy in survival of lung cancer patients who received curative treatment.

Chi-Tsung Wen, Jui-Ying Fu, Ching-Feng Wu, Ming-Ju Hsieh, Yun-Hen Liu, Yi-Cheng Wu, Ying-Huang Tsai, Ching-Yang Wu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of thoracic disease, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. International journal of clinical and experimental pathology · 2018
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Chi-Tsung Wen1 Division of Thoracic and Cardiovascular Surgery, Department of Surgery, Chang Gung Memorial Hospital, Chang Gung University, Linkou, Taiwan ; 2 Division of Chest and Critical Care, Department of Internal Medicine, Chang Gung Memorial Hospital, Chang Gung University, Taoyuan, Taiwan ; 3 Division of Chest and Critical Care, Department of Internal Medicine, Chang Gung Memorial Hospital, Chang Gung University, Chiayi, Taiwan.
Jui-Ying Fu1 Division of Thoracic and Cardiovascular Surgery, Department of Surgery, Chang Gung Memorial Hospital, Chang Gung University, Linkou, Taiwan ; 2 Division of Chest and Critical Care, Department of Internal Medicine, Chang Gung Memorial Hospital, Chang Gung University, Taoyuan, Taiwan ; 3 Division of Chest and Critical Care, Department of Internal Medicine, Chang Gung Memorial Hospital, Chang Gung University, Chiayi, Taiwan.
Ching-Feng Wu1 Division of Thoracic and Cardiovascular Surgery, Department of Surgery, Chang Gung Memorial Hospital, Chang Gung University, Linkou, Taiwan ; 2 Division of Chest and Critical Care, Department of Internal Medicine, Chang Gung Memorial Hospital, Chang Gung University, Taoyuan, Taiwan ; 3 Division of Chest and Critical Care, Department of Internal Medicine, Chang Gung Memorial Hospital, Chang Gung University, Chiayi, Taiwan.
Ming-Ju Hsieh1 Division of Thoracic and Cardiovascular Surgery, Department of Surgery, Chang Gung Memorial Hospital, Chang Gung University, Linkou, Taiwan ; 2 Division of Chest and Critical Care, Department of Internal Medicine, Chang Gung Memorial Hospital, Chang Gung University, Taoyuan, Taiwan ; 3 Division of Chest and Critical Care, Department of Internal Medicine, Chang Gung Memorial Hospital, Chang Gung University, Chiayi, Taiwan.
Yun-Hen Liu1 Division of Thoracic and Cardiovascular Surgery, Department of Surgery, Chang Gung Memorial Hospital, Chang Gung University, Linkou, Taiwan ; 2 Division of Chest and Critical Care, Department of Internal Medicine, Chang Gung Memorial Hospital, Chang Gung University, Taoyuan, Taiwan ; 3 Division of Chest and Critical Care, Department of Internal Medicine, Chang Gung Memorial Hospital, Chang Gung University, Chiayi, Taiwan.
Yi-Cheng Wu1 Division of Thoracic and Cardiovascular Surgery, Department of Surgery, Chang Gung Memorial Hospital, Chang Gung University, Linkou, Taiwan ; 2 Division of Chest and Critical Care, Department of Internal Medicine, Chang Gung Memorial Hospital, Chang Gung University, Taoyuan, Taiwan ; 3 Division of Chest and Critical Care, Department of Internal Medicine, Chang Gung Memorial Hospital, Chang Gung University, Chiayi, Taiwan.
Ying-Huang Tsai1 Division of Thoracic and Cardiovascular Surgery, Department of Surgery, Chang Gung Memorial Hospital, Chang Gung University, Linkou, Taiwan ; 2 Division of Chest and Critical Care, Department of Internal Medicine, Chang Gung Memorial Hospital, Chang Gung University, Taoyuan, Taiwan ; 3 Division of Chest and Critical Care, Department of Internal Medicine, Chang Gung Memorial Hospital, Chang Gung University, Chiayi, Taiwan.
Ching-Yang Wu1 Division of Thoracic and Cardiovascular Surgery, Department of Surgery, Chang Gung Memorial Hospital, Chang Gung University, Linkou, Taiwan ; 2 Division of Chest and Critical Care, Department of Internal Medicine, Chang Gung Memorial Hospital, Chang Gung University, Taoyuan, Taiwan ; 3 Division of Chest and Critical Care, Department of Internal Medicine, Chang Gung Memorial Hospital, Chang Gung University, Chiayi, Taiwan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMetachronous malignancy is also found in the lung cancer population and may be identified before or after diagnosis of lung cancer. No prior studies have documented lung cancer patients with metachronous malignancy and its survival impact in this population. The aim of this study was to try to clarify the survival impact of locoregional metachronous malignancy in the lung cancer population with resectable disease from a pathology point of view.

methodsFrom January 2005 to December 2009, 199 lung cancer patients received curative treatment in Chang Gung Memorial Hospital, of which 34 were identified as having lung cancer and metachronous malignancy and 165 patients as having lung cancer only. Clinico-pathologic factors were collected from the medical records. Differences in clinical presentations between the two groups and survival impact were further analyzed.

resultsOf these patients, 165 patients (82.9%) had lung cancer only (lung cancer group), and the remaining 34 patients (17.1%) had lung cancer and metachronous malignancy (metachronous malignancy group). There were no significant differences in clinical characteristics between the two groups. The disease free survival (P=0.3199) and overall survival (P=0.71) between these two groups showed no statistically significant difference. Metachronous malignancy only showed survival impact in lung cancer patients with pathologic stage IIIA (P=0.0389).

conclusionsMetachronous malignancy is also seen in the lung cancer population and may be identified before or after diagnosis of lung cancer. Locoregional metachronous malignancy has no survival impact on lung cancer patients who receive curative treatment. Anatomic resection with regional lymph node (LN) dissection is recommended if different tumor cell type and resectable disease are confirmed.

Indexed as

lung cancerMetachronous malignancysurvival

Identifiers

PMID27293830
PMCPMC4885957

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.